Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma

This study evaluates the effect of dual PI3K and mTOR inhibition using NVP-BEZ235 in preclinical models of ovarian cancer as a potential novel therapeutic strategy. Inhibition of PI3K/Akt/mTOR signaling by NVP-BEZ235 was demonstrated by immunoblotting. The effect on cell proliferation was assessed i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2011-04, Vol.17 (8), p.2373-2384
Hauptverfasser:	SANTISKULVONG, Chintda, KONECNY, Gottfried E, FEKETE, Mirela, CHEN, Kuang-Yui Michael, KARAM, Amer, MULHOLLAND, David, ENG, Carol, HONG WU, MIN SONG, DORIGO, Oliver
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic agents Antineoplastic Agents - pharmacology Biological and medical sciences Caspase 3 - metabolism Cell Cycle - drug effects Cell Line, Tumor Cell Movement - drug effects Cell Proliferation - drug effects Cisplatin - pharmacology Disease Models, Animal Drug Resistance, Neoplasm - drug effects Enzyme Activation - drug effects Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Imidazoles - therapeutic use Immunoblotting Medical sciences Mice Mice, Transgenic Mutation Ovarian Neoplasms - drug therapy Ovarian Neoplasms - metabolism Ovarian Neoplasms - pathology Pharmacology. Drug treatments Phosphatidylinositol 3-Kinases - antagonists & inhibitors Phosphatidylinositol 3-Kinases - genetics Phosphatidylinositol 3-Kinases - metabolism Phosphorylation - drug effects Proto-Oncogene Proteins c-akt - metabolism PTEN Phosphohydrolase - genetics PTEN Phosphohydrolase - metabolism Quinolines - therapeutic use Signal Transduction - drug effects TOR Serine-Threonine Kinases - antagonists & inhibitors TOR Serine-Threonine Kinases - genetics TOR Serine-Threonine Kinases - metabolism Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!